Vaccins contre l'hépatite 2026-2030

This tender for Hepatitis vaccines is generally well-structured with clear documentation and a defined procedure, but lacks specific details on evaluation criteria and financial requirements, impacting its completeness and practicality.

The tender adheres to open procedure and specifies a CPV code. Deadlines are provided, though the submission deadline appears very short relative to the publication date. No disputes are indicated. Regulatory compliance is assumed but not explicitly detailed.

The description clearly outlines the procurement of three separate framework agreements for different Hepatitis vaccines and allows bidders to offer on one, two, or all three. However, evaluation criteria are missing, which hinders clarity on how bids will be assessed.

Basic information like title, reference, organization, and CPV code are present. The value is not disclosed, and crucial details such as contract duration and specific technical/financial requirements are absent, reducing overall completeness.

The tender is an open procedure, allowing broad participation. The division into parts is fair. Access to documents is provided via external links and attachments. The lack of disclosed value and specific evaluation criteria could be perceived as less transparent, but no requirements appear tailored to specific companies.

The tender is marked as e-procurement, which is positive. However, the lack of a clear contract start date, financing information, and the absence of specific technical/financial requirements make it less practical for bidders to prepare comprehensive proposals.

Key fields such as title, reference, organization, and CPV code are populated. Dates are logical, and there are no indications of suspension or disputes. The structure is consistent across languages.

There is no explicit mention of green procurement, social aspects, innovation, or EU funding, which are common elements in modern tenders. This suggests a lack of focus on sustainability criteria.